Is Common Heir still operating in 2026?

Uncertain. Common Heir posted a 'Closing Note' on its own site saying it 'has found a new home' and is starting a 'new chapter,' referencing 'the past 4 years' of operation. No acquirer or successor has been named by any third party as of this writing.

Did Common Heir get acquired?

Unconfirmed. The company's website Closing Note claims a transition to a 'new home,' but no press release, acquirer name, or deal terms have surfaced in third-party coverage, so any acquisition remains unverified as of the site's current state.

How much funding did Common Heir raise?

Common Heir raised a $2.5 million seed round from Trousdale Ventures and Mucker Capital, announced February 16, 2022, exceeding its original target by over $1 million. No Series A or later round has been publicly disclosed since.

Is Common Heir profitable?

No profitability figures are disclosed. By January 2023 sales had grown 3x year over year with DTC at about 70% of revenue, but the company is private with no earnings reports, and peak reported traction stayed under $1 million.

Who is Common Heir's biggest competitor?

e.l.f. Beauty, via its Naturium and rhode brands, is the named incumbent threat; e.l.f. reported over $1.6 billion in FY sales and 35% Q4 growth (as of a 2026-05-20 reference), dwarfing Common Heir's sub-$1M scale.

Can I still buy Common Heir products?

Partially. As of the current storefront, the Vitamin C Serum and Ceramide Serum are listed sold out, while the Retinol Serum and Gua Sha Facial Sculptor remain available, alongside the site's Closing Note about a brand transition.

Consumer brands · acquisition pending · United States

Common Heir

commonheir.com ↗

Small US skincare brand selling minimalist, sustainable vitamin C and ceramide serums direct to consumer.

Little protection left

Assessed 23 July 2026 · Evidence as of 23 July 2026

Not much stands between this business and its pressures.

On the recordSince 23 July 2026 · Checkable from H1 2026 · Every call on the record Checkpoint: Confirmation of the named acquirer or operator behind the promised 'new home' relaunch

The call

Common Heir's own website says the brand is closing this chapter, with sold-out shelves, no restocks, and no confirmed buyer for whatever comes next.

Common Heir sold vitamin C serums and ceramide moisturizers online, competing in a crowded beauty market against much larger brands like e.l.f. Beauty and Naturium. The company only raised $2.5 million in 2022, never got a bigger funding round, and made less than $1 million in peak revenue, while bigger rivals scaled to over $1 billion by offering similar products at lower prices and with better store placement. The company posted a farewell message saying it is moving to a 'new home' and its products are sold out, suggesting the business in its current form is ending, though it is unclear if another company is buying the brand or if it is simply shutting down.

Why

AI pressure: None apparent. AI tools help shoppers compare serums and find cheaper dupes, but the bigger problem is Common Heir ran out of money first. Could AI do the core job? Only partly.

Bigger players: e.l.f. Beauty (Naturium, rhode distribution machine). e.l.f. scaled Naturium past $1.6B while Common Heir posted a Closing Note, sold out its core serums, and stopped launching new products after 2023. Could a giant copy it? Yes, easily.

What protects it. None apparent, the brand itself says it is closing this chapter.

What would change this call

Named acquirer or 'new home' confirmed by a third party within 6 months. Would show a real successor entity exists rather than a quiet wind-down.
Vitamin C and Ceramide serums restock on commonheir.com. Would show continued operations rather than inventory exhaustion.
Any new product launch or Sephora/Ulta listing in 2026. Would show the brand is still actively competing, not shutting down.

Key numbers

$2.5M total seed raised, no Series A (Feb 2022)
Est. revenue ~$956K, likely stale (n.d.)
Zero new product launches (since 2023)

Named risks

Closing Note signals possible wind-down with no confirmed acquirer or deal terms. Severity: high
Core SKUs (Vitamin C Serum, Ceramide Serum) sold out on storefront. Severity: high
No product launches reported by third parties since 2023. Severity: medium
No follow-on funding since Feb 2022 seed round. Severity: high
Absent from all major 2025-2026 competitive 'best of' media roundups. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
e.l.f. Beauty (Naturium/rhode)	losing to	e.l.f. posted >$1.6B FY sales and 35% Q4 growth vs Common Heir's sub-$1M scale, as of 2026-05-20
Versed, Drunk Elephant, SkinCeuticals, Paula's Choice, Timeless, Sunday Riley	losing to	Dominated 2025-2026 'best vitamin C serum' roundups while Common Heir was absent
Topicals	contesting	Shares investor Mucker Capital; competing DTC skincare brand as of 2022-02-16 report
Sephora and Ulta Beauty (retail gatekeepers)	losing to	No Sephora or Ulta listing found for Common Heir as of 2023-01-17 reporting

Questions people ask

Is Common Heir still operating in 2026?: Uncertain. Common Heir posted a 'Closing Note' on its own site saying it 'has found a new home' and is starting a 'new chapter,' referencing 'the past 4 years' of operation. No acquirer or successor has been named by any third party as of this writing.
Did Common Heir get acquired?: Unconfirmed. The company's website Closing Note claims a transition to a 'new home,' but no press release, acquirer name, or deal terms have surfaced in third-party coverage, so any acquisition remains unverified as of the site's current state.
How much funding did Common Heir raise?: Common Heir raised a $2.5 million seed round from Trousdale Ventures and Mucker Capital, announced February 16, 2022, exceeding its original target by over $1 million. No Series A or later round has been publicly disclosed since.
Is Common Heir profitable?: No profitability figures are disclosed. By January 2023 sales had grown 3x year over year with DTC at about 70% of revenue, but the company is private with no earnings reports, and peak reported traction stayed under $1 million.
Who is Common Heir's biggest competitor?: e.l.f. Beauty, via its Naturium and rhode brands, is the named incumbent threat; e.l.f. reported over $1.6 billion in FY sales and 35% Q4 growth (as of a 2026-05-20 reference), dwarfing Common Heir's sub-$1M scale.
Can I still buy Common Heir products?: Partially. As of the current storefront, the Vitamin C Serum and Ceramide Serum are listed sold out, while the Retinol Serum and Gua Sha Facial Sculptor remain available, alongside the site's Closing Note about a brand transition.

Timeline

2026-05-28Absent from NBC News 'Best Vitamin C Serums of 2026' roundup
2025-06-18Absent from Byrdie 'Best Vitamin C Serums of 2025' roundup
2024-02-29Byrdie covers Ceramide Barrier Boost Serum, last reported new product
2023-01-17Sales reported up 3x YoY, DTC about 70% of revenue
2023-01Company staffed by two full-time employees plus two co-founders
2022-03-12Sources project at least $500K in 2022 sales
2022-02-16Common Heir raises $2.5M seed round from Trousdale Ventures and Mucker Capital
2022-02-150.2% Retinol Serum launches, formulated for melanin-rich skin
2021-05-18Credo Beauty retail partnership announced
2021-04-06Public launch with 10% Vitamin C Serum in biodegradable capsules

Revision history

23 July 2026

First assessed. Little protection left. The text above is fixed as of this date and is not edited afterwards.

In the same band

Lulus Fashion Lounge Holdings, Inc.Allbirds Esprit Holdings Limited